Partnering with microbiologists to diagnose and prevent diseaseTM

In October, Hardy gained clearance from the FDA to market the new Carba 5 lateral flow device that detects the five main bacterial enzymes of Carbapenem resistance. Test results are obtained in only 15 minutes and the cost is far less than PCR. Another benefit is that it tests for the phenotypic expression of the resistance gene, rather than just the gene itself.  Hardy partnered with a French company to market this innovative new life-saving product in the United States on an exclusive basis.